Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EXEL)

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

Business Wire 6 days ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

Business Wire February 27, 2024

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Business Wire February 6, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

Business Wire February 1, 2024

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Business Wire January 25, 2024

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

Business Wire January 23, 2024

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Business Wire January 22, 2024

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

Business Wire January 18, 2024

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Business Wire January 7, 2024
View More News ››

Opinion & Analysis (NDAQ:EXEL)

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Streetwise Reports April 21, 2020

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

Stock picks including a coal play

J.W. Cotton November 4, 2009
View More Opinion ››

Bullboard Posts (NDAQ:EXEL)

fighting cancers

with a profitable operation valued at about $7 billion and a diverse portfolio of treatments. These include its Cabometyx drug for...
jw1trader - August 24, 2022

FYI (Seeking Alpha) Bret Jensen

I offer up three predictions that are highly probable in my opinion for Gilead in 2017 and its shareholders. 1. The dividend is hiked...
Carlos66 - January 11, 2017

RE:Anyone watching this?

I'm in let see what happen soon?? Mark
mark26 - August 16, 2014

Anyone watching this?

this is going to JUMP! $11 dollar target set by Piper Jaffray... get in this quick!!! http://www.fool.com/investing/general/2014/04/04...
stopstockingme - April 6, 2014

Venture Exchange News

http://www.tsx.com/en/news_events/news_releases/10-5-2007_TSXVenture-NewListingELE.html EXCELSIOR ENERGY LIMITED ("ELE"...
Oldmannorth - October 9, 2007

RE: Excelsior News - Sept 25

Bye Bye CNQ, hello TSX Venture. New symbol is ELE starts trading Tuesday October 9th.
britexile - October 9, 2007
View more Bullboard ››

Bitcoin Well Inc

Bitcoin Well Inc

Bitcoin Well Inc. is a Canada-based company engaged in the non-custodial fintech business, which future-proofs money by ...
View More »